New drug cocktail aims to stop liver cancer from coming back
NCT ID NCT07160361
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tests whether giving a combination of two drugs—lenvatinib and losartan—after surgery can lower the chance of liver cancer returning in patients whose tumors show 'tumor budding,' a sign of aggressive disease. The drugs work by breaking down collagen barriers around cancer cells and targeting the cells directly. The trial will follow 56 patients for two years to see how many have their cancer come back.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
lenvatinib and losartan
What this could lead to
If successful, this combination could offer a new way to reduce the risk of liver cancer returning after surgery for patients with tumor budding.
What could go wrong
This is a small, early-phase study with only 56 participants, so results may not apply to everyone. The combination may cause side effects or fail to prevent recurrence.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARCINOMA, HEPATOCELLULAR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••